The Evaluation of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes

Registry ID

EUCTR2010-022297-14

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

REATA PHARMACEUTICALS INC

Start date

2012-04-17

Completion date

2012-11-15

Last update

2026-08-16

Conditions

• Chronic Kidney Disease Stage 4

Summary

To assess the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular death in patients with Stage 4 CKD and type 2 diabetes receiving standard of care

Locations

• , , UK
• , , Czechia
• , , Austria
• , , Spain
• , , Belgium
• , , Germany
• , , Sweden
• , , Italy

Related clinical trials

• The Agenda-Setting for Kidney Disease Open Pilot Trial
• Kidney Transplant Improvement Through New Exercise Training to Increase Capacity
• A Communication-Priming Intervention to Improve Shared Decision-Making Between Older Adults With Advanced CKD and Clinicians

View on source registry